- Home
- PHUN vs SKYE Comparison
PHUN vs SKYE Comparison
Compare PHUN & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHUN
- SKYE
- Stock Information
- Founded
- PHUN 2009
- SKYE 2012
- Country
- PHUN United States
- SKYE United States
- Employees
- PHUN N/A
- SKYE 16
- Industry
- PHUN EDP Services
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- PHUN Technology
- SKYE Health Care
- Exchange
- PHUN Nasdaq
- SKYE Nasdaq
- Market Cap
- PHUN 64.1M
- SKYE 115.9M
- IPO Year
- PHUN N/A
- SKYE N/A
- Fundamental
- Price
- PHUN $3.52
- SKYE $4.30
- Analyst Decision
- PHUN Buy
- SKYE Buy
- Analyst Count
- PHUN 2
- SKYE 6
- Target Price
- PHUN $7.75
- SKYE $16.60
- AVG Volume (30 Days)
- PHUN 346.3K
- SKYE 2.1M
- Earning Date
- PHUN 08-07-2025
- SKYE 08-08-2025
- Dividend Yield
- PHUN N/A
- SKYE N/A
- EPS Growth
- PHUN N/A
- SKYE N/A
- EPS
- PHUN N/A
- SKYE N/A
- Revenue
- PHUN $2,956,000.00
- SKYE N/A
- Revenue This Year
- PHUN $3.01
- SKYE N/A
- Revenue Next Year
- PHUN $50.72
- SKYE N/A
- P/E Ratio
- PHUN N/A
- SKYE N/A
- Revenue Growth
- PHUN N/A
- SKYE N/A
- 52 Week Low
- PHUN $2.22
- SKYE $1.14
- 52 Week High
- PHUN $14.60
- SKYE $7.47
- Technical
- Relative Strength Index (RSI)
- PHUN 60.52
- SKYE 67.91
- Support Level
- PHUN $3.25
- SKYE $3.92
- Resistance Level
- PHUN $3.10
- SKYE $4.75
- Average True Range (ATR)
- PHUN 0.17
- SKYE 0.66
- MACD
- PHUN 0.04
- SKYE 0.09
- Stochastic Oscillator
- PHUN 94.37
- SKYE 60.70
About PHUN Phunware Inc.
Phunware Inc is a software company. It is a cloud platform for mobile that provides companies with the products, solutions, and data and services necessary to engage, manage and monetize its mobile application audiences. It derives maximum revenue from United States. The company has two reportable segments: Software subscriptions and services; and Advertising. It derives maximum revenue from Software subscriptions and services.
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.